InVivoMab anti-human CD40 BE0189-R100mg from Bio X Cell

Product Specs
ItemInVivoMab anti-human CD40
CompanyBio X Cell
Price $4,651.50Supplier Page View Company Product Page
Catalog NumberBE0189-R100mg
Quantity100 mg
ApplicationsAgonistic Antibodies, Flow Cytometry, Functional Assays
ConcentrationLot-Specific
Conjugate/TagUnconjugated
FormatPBS, pH 7.0, Contains no stabilizers or preservatives, Liquid
Purity≥95% Determined by SDS-PAGE
ReactivityHuman
IsotypeMouse IgG1, κ
CloneG28.5
Hostmouse
Antibody TypePrimary Antibody
ImmunogenHuman tonsillar lymphocytes
NCBI Full Gene NameCD40 molecule
NCBI Gene AliasesBp50, CDW40, TNFRSF5, p50
ClonalityMonoclonal
Research AreaImmune Checkpoint Protein, Immunology, Innate Immunity, CD Markers
StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze
Molecular Weight150 kDa
ModificationsNo
OriginUnited States

Endotoxin: ≤1EU/mg (≤0.001EU/µg), Determined by LAL gel clotting assay

Quantities Available: 1mg, 5mg, 25mg,50mg, 100mg, Additional Custom Sizing Available on bioxcell.com

39 Labombard Rd

Lebanon, NH 03766

United States

Phone: 1-866-787-3444

Email: customerservice@bioxcell.com

(1) The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapyFrontiers in immunologyJanuary 1, 2023Frankish J, Mukherjee D, Romano E, Billian-Frey K, Schröder M, Heinonen K, Merz C, Redondo Müller M, Gieffers C, Hill O, et al.incubated with a commercially available mouse anti human CD40 antibody (clone G28.5, Bio X Cell, Cat No. BE0189R005MG). IP of TRAF2 and TRAF6: Protein G Dynabeads were incubated with mouse-anti-human TRAF2 (R&D Systems

(2) CD4⁺ T Cells in the Blood of MS Patients Respond to Predicted Epitopes From B cell Receptors Found in Spinal FluidFrontiers in immunologyJanuary 1, 2020Høglund RA, Bremel RD, Homan EJ, Torsetnes SB, Lossius A, Holmøy T.

(3) Induction of an altered CD40 signaling complex by an antagonistic human monoclonal antibody to CD40Journal of immunology (Baltimore, Md. : 1950)May 1, 2015Bankert KC, Oxley KL, Smith SM, Graham JP, de Boer M, Thewissen M, Simons PJ, Bishop GA.

(4) Increased B Cell ADAM10 in Allergic Patients and Th2 Prone MicePloS oneJanuary 1, 2015Cooley LF, Martin RK, Zellner HB, Irani AM, Uram-Tuculescu C, El Shikh ME, Conrad DH.

(5) Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effectsAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant SurgeonsJune 1, 2014Okimura K, Maeta K, Kobayashi N, Goto M, Kano N, Ishihara T, Ishikawa T, Tsumura H, Ueno A, Miyao Y, et al.

(6) CD40L expression permits CD8+ T cells to execute immunologic helper functionsBloodJuly 18, 2013Frentsch M, Stark R, Matzmohr N, Meier S, Durlanik S, Schulz AR, Stervbo U, Jürchott K, Gebhardt F, Heine G, et al.

(7) CD40 pathway activation reveals dual function for macrophages in human endometrial cancer cell survival and invasionCancer immunology, immunotherapy : CIIFebruary 1, 2013Dumas G, Dufresne M, Asselin É, Girouard J, Carrier C, Reyes-Moreno C.

(10) Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14Cancer researchJune 15, 2000Francisco JA, Donaldson KL, Chace D, Siegall CB, Wahl AF.

InVivoMAb anti-human CD40